Panobacumab is a monoclonal antibody designed for therapeutic use, primarily targeting specific bacterial infections. It is engineered to bind to the surface proteins of certain pathogens, thereby neutralizing their ability to cause disease. This characteristic makes it a valuable tool in the treatment of infections, particularly those caused by antibiotic-resistant bacteria. The molecular structure of Panobacumab includes regions that facilitate its binding to antigens, enhancing its efficacy in immune response modulation. As a biologic agent, it is produced through recombinant DNA technology, ensuring a high degree of specificity and potency. Panobacumab's pharmacokinetics typically involve a prolonged half-life due to its antibody nature, allowing for less frequent dosing compared to traditional antibiotics. Safety profiles are generally assessed through clinical trials, focusing on potential immunogenicity and adverse effects. Overall, Panobacumab represents a significant advancement in the field of infectious disease treatment, particularly in the context of rising antibiotic resistance.

Panobacumab

885053-97-4: Panobacumab is a monoclonal antibody designed for therapeutic use, primarily targeting specific bacterial infections. It is engineered to bind to the surface proteins of certain pathogens, thereby neutralizing their ability to cause disease. This characteristic makes it a valuable tool in the treatment of infections, particularly those caused by antibiotic-resistant bacteria. The molecular structure of Panobacumab includes regions that facilitate its binding to antigens, enhancing its efficacy in immune response modulation. As a biologic agent, it is produced through recombinant DNA technology, ensuring a high degree of specificity and potency. Panobacumab's pharmacokinetics typically involve a prolonged half-life due to its antibody nature, allowing for less frequent dosing compared to traditional antibiotics. Safety profiles are generally assessed through clinical trials, focusing on potential immunogenicity and adverse effects. Overall, Panobacumab represents a significant advancement in the field of infectious disease treatment, particularly in the context of rising antibiotic resistance.

<p>Anti-Human serotype IATS O11 Monoclonal Antibody</p>

<p>Panobacumab (KBPA101) is a human IgM/κ monoclonal antibody targeting P. aeruginosa serotype O11 LPS O polysaccharide.</p>

CAS 885053-97-4

Panobacumab

Panobacumab

Ref: 3D-CLA1187

Panobacumab

Ref: TM-T76755